Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience
IntroductionThymoma-associated myasthenia gravis (TAMG) accounts for 15–20% of all myasthenia gravis (MG) cases and is typically characterized by severe clinical manifestations and suboptimal response to conventional therapies. However, TAMG patients a…